Japanese Site Map
Message Overview Research Laboratories Events / Publications Admission Access map
Home > Research Laboratories
Collaborative institutes Laboratoryof Immune Regulation Chugai Pharmaceutical CO.,LTD.
Nanobiology Laboratories
Soft Biosystem Group
Protonic NanoMachine Group
Sensory Transduction Group

Biomolecular Networks Laboratories
Research Group of Lipid Biosignals
Biomolecular Dynamics Group
Developmental Biology Group
Chromosome Replication Group

Integrated Biology Laboratories
Laboratory of Genetics
Pathology Division
KOKORO-Biology Group
Cellular Biology Group

Organismal Biosystems Laboratories
Laboratory of Developmental Immunology
Developmental Genetics Group
Human Cell Biology Group
Medicine and Pathophysiology Group

Neuroscience Laboratories
Visual Neuroscience Group
Developmental and Functional Neuroscience Group
Cognitive Neuroscience Group
Cellular and Molecular Neurobiology Group
Synaptic Plasticity Group

Biophysical Dynamics Laboratories
Physiological Laboratory
Nonequilibrium Physics Group
Functional Proteomics Group
Nano-Biophotonics Group

Biomedical Engineering Laboratories
Systems Neuroscience Group
Department of Molecular Genetics
Laboratory of Intercellular Communications
Laboratory of Stem Cell Research
Laboratory of Protein Informatics
Laboratory of Biocatalysis Science

Collaborative institutes
Collaborative institutes Laboratory of Immune Regulation Chugai Pharmaceutical CO., LTD.
Optical Nano Device Group
OMRON Corporation

Professor KISHIMOTO Tadamitsu, MD, PhD. TEL +81-6-6879-4431
FAX +81-6-6879-4437
Associate Professor Shigemi Kinoshita, PhD. TEL  
Assistant Professor Akihiro Kimura, PhD. TEL +81-6-6879-4432

Postal Mail Address Laboratory of Immune Regulation, Graduate School of Frontier Biosciences, Osaka University 1-3 Yamadaoka, Suita, Osaka 565-0871 Japan
Lab Web site http://www.ifrec.osaka-u.ac.jp/jpn/laboratory/immuneregulation/index.php
Collaborations Laboratory for Immune Signal, National Institute of Biomedical Innovation (http://www.nibio.go.jp/kisoteki/meneki_signal.html)


Interleukin-6 (IL-6)? IL-6 is a multifunctional cytokine produced by lymphoid and nonlymphoid cells; it regulates immune responses, acute-phase reactions, and inflammation. IL-6 signaling is mediated exclusively by the common signal-transducing component gp130, which is also essential for signal transduction of other cytokines of the leukemia inhibitory factor (LIF)/IL-6 family. Blocking IL-6 actions by use of a humanized antibody, tocilizumab, which targets the IL-6 receptor, has been proven to be therapeutically effective for rheumatoid arthritis, systemic juvenile idiopathic arthritis, Castleman disease and Crohn's disease. Regulatory system of IL-6 in Treg/Th17 development?Recently, a new subset of Th cells producing IL-17 (Th17) has been identified and shown to have a crucial role in the induction of autoimmune diseases such as rheumatoid arthritis and experimental autoimmune encephalomyelitis (EAE) as well as allergen-specific responses. Th17 cells differentiation is driven by the combination of IL-6 and TGF-?, whereas IL-6 inhibits the development of regulatory T (Treg) cells by TGF-?. Our current research is focused on demonstrating how IL-6 controls the generation of Treg/Th17 cells. We not only revealed the framework of cytokine signaling, including identification of the IL-6 receptor, gp130, NF-IL6, STAT3, and SOCS-1, but also led to the development of a new therapy for chronic inflammatory diseases. Recent studies demonstrated that Th17, distinct from Th1 and Th2, is the main pro-inflammatory CD4+ effector T cell involved in CIA and EAE. Understanding the precise mechanisms of Th17 differentiation by IL-6 will lead to resolve the immune disorder that causes immune-mediated inflammatory diseases.
figure 1
figure 2

figure 3



Page Top


All rights reserved. Copyright © 2003 Graduate School of Frontier Biosciences, Osaka University